Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$10.47
-2.1%
$8.62
$3.75
$11.40
$167.73M2.7364,287 shs55,837 shs
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$1.45
-0.3%
$1.40
$1.05
$5.17
$156.47M0.381.20 million shs402,410 shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$2.10
+4.2%
$1.87
$0.78
$3.39
$149.72M0.931.41 million shs873,571 shs
Zomedica Corp. stock logo
ZOMDF
Zomedica
$0.04
-0.8%
$0.05
$0.02
$0.17
$38.61M1.474.73 million shs539,355 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
0.00%+15.05%+11.62%+136.34%+1,046,999,900.00%
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
0.00%-1.70%-5.56%+8.65%+20.42%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
0.00%-10.09%-14.47%+151.64%-3.49%
Zomedica Corp. stock logo
ZOMDF
Zomedica
0.00%-2.72%-11.46%-14.53%-73.05%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
1.6867 of 5 stars
3.50.00.00.02.30.80.0
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
2.4047 of 5 stars
3.62.00.00.01.91.70.6
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
2.3747 of 5 stars
3.43.00.00.00.62.50.6
Zomedica Corp. stock logo
ZOMDF
Zomedica
0.234 of 5 stars
0.05.00.00.00.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
3.00
Buy$20.0091.02% Upside
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.11
Buy$9.71572.27% Upside
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
2.75
Moderate Buy$10.00375.29% Upside
Zomedica Corp. stock logo
ZOMDF
Zomedica
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ZOMDF, ACRS, VTYX, and ACOG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/23/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
5/28/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$8.00
5/16/2025
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/14/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $16.00
5/9/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/AN/AN/AN/A$2.59 per shareN/A
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$18.72M8.36N/AN/A$1.44 per share1.00
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/A$3.59 per shareN/A
Zomedica Corp. stock logo
ZOMDF
Zomedica
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$14.64M-$1.20N/AN/AN/A-65.83%-48.21%8/11/2025 (Estimated)
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$135.12M-$1.75N/AN/AN/AN/A-47.45%-43.49%8/14/2025 (Estimated)
Zomedica Corp. stock logo
ZOMDF
Zomedica
N/A-$0.11N/AN/AN/AN/AN/AN/A

Latest ZOMDF, ACRS, VTYX, and ACOG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million
5/8/2025Q1 2025
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$0.48-$0.39+$0.09-$0.39N/AN/A
5/6/2025Q1 2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/AN/AN/AN/AN/A
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/AN/A
Zomedica Corp. stock logo
ZOMDF
Zomedica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
17.14
16.83
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
5.06
5.06
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/A
19.57
19.57
Zomedica Corp. stock logo
ZOMDF
Zomedica
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
97.88%
Zomedica Corp. stock logo
ZOMDF
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
14.00%
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
6.40%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
18.18%
Zomedica Corp. stock logo
ZOMDF
Zomedica
5.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A16.02 million13.78 millionN/A
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
100108.28 million101.35 millionOptionable
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
3071.16 million58.22 millionOptionable
Zomedica Corp. stock logo
ZOMDF
Zomedica
50979.95 millionN/AN/A

Recent News About These Companies

Zomedica Corp. (ZOMDF)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alpha Cognition stock logo

Alpha Cognition NASDAQ:ACOG

$10.47 -0.22 (-2.06%)
As of 07/3/2025 01:00 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$1.44 -0.01 (-0.34%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.44 0.00 (0.00%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Ventyx Biosciences stock logo

Ventyx Biosciences NASDAQ:VTYX

$2.10 +0.08 (+4.16%)
Closing price 07/3/2025 03:35 PM Eastern
Extended Trading
$2.13 +0.02 (+1.19%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Zomedica stock logo

Zomedica OTC:ZOMDF

$0.04 0.00 (-0.76%)
As of 07/3/2025 12:58 PM Eastern

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.